GU Cast | Urology Podcast

Professor Declan Murphy & Dr Renu Eapen
  • 0.0（0）
  • 医学
  • アップデート：隔週

A urology podcast, focussing on prostate cancer, kidney cancer, bladder cancer, testis and penile cancer. Join Professor Declan Murphy and Dr Renu Eapen from Peter MacCallum Cancer Centre in Melbourne for this regular dive into the world of genitourinary (GU) Oncology and Urology. Regular guests from all over the world, from every walk of life. Find out more gucast.org 

  1. 1日前

    Timing, touch & technique: Batting lessons for nerve-sparing radical prostatectomy | With Ash Tewari

    Tips and tricks for nerve-sparing surgery, learned over 25 years of performing robotic radical prostatectomy. Today we are joined by Dr Ash Tewari, Chief of Urology at Mt Sinai (New York), to talk about his favourite topic - nerve-sparing surgery - and a little about his second favourite topic - cricket! Ash has been one of the world's foremost experts in robotic prostatectomy having been there at the very start when Mani Menon was developing the technique, and has studied the anatomy of nerve-sparing prostatectomy in fine detail. Today we chat through his thoughts on the optimal approach to nerve-sparing prostatectomy to deliver the best outcomes for our patients. Some surgical footage included on the YouTube version. This is a Themed Podcast supported by our Silver Partner, Device Technologies. Links: 7th International Prostate Cancer Symposium December 2025 - Lecture on nerve-sparing surgery  Mt Sinai Symposium at AUA, May 2026 - Lecture on nerve-sparing surgery

    30分

  2. 6月29日

    Berlin Masterclass | Advanced prostate cancer

    Hot topics in a hot city!! Declan and Renu escaped from deep Winter in Melbourne and landed into the hottest day on record in Berlin!! We are here to help with the Astellas Global Prostate Cancer Masterclass, a wonderful two day meeting focussing on advanced prostate cancer. Delegates from all over the world and a top class local and International faculty. We catch up with great friends of GU Cast Stephen Freedland (Cedars-Sinai Medical Centre, Los Angeles) and Bertrand Tombal (UC Louvain, Brussels), to pick their brains on hot topics in this hot city. This is a Themed Podcast supported by our Platinum Partner, Astellas. Even better on our YouTube channel

    33分

  3. 6月24日

    EV-pembro in localised and advanced bladder cancer - a superb summary!

    All you need to know about enfortumab vedotin (EV) & pembro in bladder cancer in 25 minutes! We are joined in studio by bladder cancer gurus Shilpa Gupta (Cleveland Clinic, USA) and Andrew Weickhardt (Austin Health, AUS) to get an update on the role of EV-pembro in both muscle-invasive localised bladder cancer, and metastatic bladder cancer. Shilpa led a very nice paper in this month's European Urology titled optimal management of muscle, invasive bladder, cancer, so we were very keen to pick her brains on this, especially the emerging role of peri-operative EV-pembro. We also picked herself and Andrew‘s brains for the optimal management of metastatic bladder cancer, as they were both involved in the historic EV 302 trial which has transformed the management of metastatic bladder cancer. Must know stuff! A great overview of where we stand today. Thanks so much to Shilpa for dropping into Gu Cast while on holidays in Australia!  With your usual hosts are Declan Murphy and Reno Eapn This is a Themed Podcast, supported by our Platinum Partners, Astellas Disclaimer: Enfortumab vedotin in combination with pembrolizumab is not registered for MIBC in Australia and a number of other countries. Please refer to the registration status in your country before prescribing Links: Eur Urol paper on optimal management of MIBC

    33分

  4. 6月20日

    Testis cancer and miR-371 - all you need to know!

    Yep it's been a buzz word in testis cancer for a while now, but with the read-out of the CLIMATE and SWOG 1823 trials in the past six months, we thought we better get ourselves updated on this exciting biomarker. We are joined in studio by testis cancer gurus Ben Tran (Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne), and online by Aditya Bagrodia (Urologist, UCSD, San Diego), to give us a bluffers guide to miR-371. Plus we hear about the fantastic MaGIC Consortium global testis cancer meeting which takes place in Melbourne 8-11 January 2027. See links below. A great excuse to come to Melbourne, especially to escape the Northern Hemisphere winter! Links: MaGIC Consortium Conference, January 2027 Some coverage of the ANZUP CLIMATE trial from ASCO GU 2026 Some coverage of the SWOG 1823 trial from ASCO 2026

    25分

  5. 6月13日

    Journal club #8 | PROTECT and EV-301

    Welcome to Episode 8 of our monthly GU Cast Journal Club! Today we focus on two very important papers in localised prostate cancer and metastatic bladder cancer. The landmark 15 year update of the PROTECT trial, published in NEJM in 2023, and the breakthrough EV-301 trial which heralded enfortumab vedotin in progressive metastatic bladder cancer, published in NEJM in 2021. We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Mexico City, MEX), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. Links to papers below: 1. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer NEJM 2023 2. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma NEJM 2021 Even better on our YouTube channel About GU Cast Journal Club: Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology . The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner . The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

    23分

  6. 6月9日

    Bayer Apex comes to Melbourne!

    Renu had been to an excellent Bayer Apex meeting in Europe in the past, so was very happy to hear Apex was coming to us for its first Asia-Pacific outing! A wonderful prostate cancer Faculty headlined by Neal Shore, Dan George, Derya Tilki, Fred Saad, Amit Bahl, Tamim Niazi to name but a few, plus almost 200 delegates from across the APAC region.  Your usual hosts Renu Eapen and Declan Murphy catch up with some of the speakers and bring you conference highlights. This is a Themed Podcast, supported by our Gold Partner, Bayer Pharmaceuticals.

    26分

  7. 5月31日

    Did PROTEUS just change Urology??

    Breaking News podcast just after the long-awaited PROTEUS trial reads out at the ASCO Plenary in Chicago! Plus a simultaneous NEJM paper! Huge day for prostate cancer surgery.  Declan and Renu are joined by lead author Dr Mary-Ellen Taplin (Dana Farber Cancer Institute & Harvard University), to tell us about her decades long journey to this huge moment today. PROTEUS is a huge (2,100 men) phase III RCT of men undergoing radical prostatectomy for high-risk prostate cancer, randomised to receive peri-operative ADT + placebo, or ADT plus apalutamide. Mary-Ellen talks to us about the top-line results, and we consider whether this is truly a practice-changing study. Declan also had the honour of being the Discussant at teh ASCO Plenary so he is well placed to give his opinion.  Your usual hosts are Declan Murphy & Renu Eapen.  Even better on our YouTube channel This is a Themed Podcast supported by our Gold Partner, Johnson & Johnson. Links: PROTEUS NEJM paper

    39分

  8. 5月17日

    ARASEC and Lead-in ADT - China focus

    Two interesting papers caught the eye of our GU Cast China team this week; the first is the ARASEC trial which Dr Rana McKay read out in the Practice-Changing Plenary at the AUA Annual Meeting in Washington. This is an interesting comparison of ADT + darolutamide  for mHSPC in a prospective US cohort, compared with an historical ADT-only control arm from CHAARTED. Interesting study design and interesting results.  The second is the ADT Lead-In study led bu GU Cast China Editor, Dr Yao Zhu, which demonstrates how the timing of docetaxel chemotherapy in mHSPC can significnatly affect the likelihood of severe neutropenia.  Your usual hosts, Declan Murphy and Renu Eapen, anre joined by Dr Yao Zhu (Fudan University, Shanghai), Dr Yige Bau (SCU Xiamen), and Dr Chuguan Yang (Tonji Hospital, Wuhan). Yige now also part of our GU Cast China team, looking after our We Chat content with Yao Zhu.  This is a Themed Podcast supported by our GU Cast China Partner, Bayer Pharmaceuticals.

    32分
すべて見る（238）

番組について

A urology podcast, focussing on prostate cancer, kidney cancer, bladder cancer, testis and penile cancer. Join Professor Declan Murphy and Dr Renu Eapen from Peter MacCallum Cancer Centre in Melbourne for this regular dive into the world of genitourinary (GU) Oncology and Urology. Regular guests from all over the world, from every walk of life. Find out more gucast.org 

情報

  • クリエイター
    Professor Declan Murphy & Dr Renu Eapen
  • 配信期間
    20年 - 26年
  • エピソード
    238
  • 制限指定
    不適切な内容を含まない
  • Copyright
    © 2026 GU Cast | Urology Podcast
  • 番組のWebサイト
    GU Cast | Urology Podcast

その他のおすすめ